Takeda expands in Brazil with Multilab buy
This article was originally published in Scrip
Takeda has agreed to pay up to Real540 million ($270 million) for the Brazilian company Multilab Indústria e Comércio de Produtos Farmacêuticos, expanding its reach in an important emerging market and also into the branded generics segment in the country.
You may also be interested in...
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.